WX [WuXi PharmaTech (Cayman)] 6-K: (Original Filing)
[WuXi PharmaTech (Cayman) Inc. Form 6-K 3 4 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3]
SVA [SINOVAC BIOTECH] 6-K: Sinovac Provides Updates on Pipeline Vaccines BEIJING, March
[Sinovac Provides Updates on Pipeline Vaccines BEIJING, March 17, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. ), a leading provider of biopharmaceutical products in China, today provided updates on the Company's pipeline vaccines. EV71 vaccine. EV71 is a virus that causes hand, foot and mouth disease (HFMD) and is the primary cause of most severe and fatal cases of hand, foot] [Sinovac to Participate in China Medical and Healthcare Investment Conference Beijing, March 18,2014/PRNewswire/--Sinovac Biotech Ltd.(NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that the Company will participate in the China Medical and Healthcare Investment Conference sponsored by T.H capital and Dong Xing Security, to be held at China World Hotel from March 23 to March 25. The] [Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2014 Unaudited Financial Results BEIJING, April 10, 2015 -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the fourth quarter and full year, ended December 31, 2014, before market opens on Monday,] []
SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: (Original Filing)
[SKYSTAR BIO-PHARMACEUTICAL COMPANY ANNOUNCES RECEIPT OF NASDAQ NON-COMPLIANCE LETTER DUE TO DELAY IN FILING FORM 10-K Xi’an, China, April 15, 2015 – Skystar Bio-Pharmaceutical Company (Nasdaq: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that the Company received a notification from the Nasdaq Stock Market (“Nasdaq”) informing the Company that since it] [805 King Farm Blvd. Rockville, MD 20850 / USA Nasdaq.com By Electronic Delivery to: bing@skystarbio-pharmaceutical.com; aorudjev@schiffhardin.com; scramer@skystarbio-pharmaceutical.com April 15, 2015 Mr. Bing Mei Chief Financial Officer Skystar Bio-Pharmaceutical Company 4/F Building B, Chuangye Square, No. 48 Keji Road Gaoxin District, Xi’an Shaanxi Province, P.R. China Re: Skystar Bio-Pharmaceutical Company (the “Company”) Nasdaq Symbol: SKBI Dear Mr. Mei: 1 I am] []
WX [WuXi PharmaTech (Cayman)] 6-K: WuXi PharmaTech (Cayman) Inc. Form 6-K 3 4
[WuXi PharmaTech (Cayman) Inc. Form 6-K 3 4 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3]
BSPM [Biostar Pharmaceuticals] 8-K: (Original Filing)
[Biostar Pharmaceuticals, Inc. Announces Its Full Year and Fourth Quarter 2014 Financial Results Full Year 2014 Financial Highlights · Net sales increased by $8.7 million, or 16.5%, year over year, from $52.7 million in 2013 to $61.4 million in 2014. · Gross profit grew by approximately 17.9% from $25.7 million in 2013 to $30.3 million in 2014. · Cash and] [FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): April 15, 2015 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue, Xianyang City, Shaanxi Province, People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ¨ ¨ ¨]
BSPM [Biostar Pharmaceuticals] 8-K: Biostar Pharmaceuticals, Inc. Announces Its Full Year and
[Biostar Pharmaceuticals, Inc. Announces Its Full Year and Fourth Quarter 2014 Financial Results Full Year 2014 Financial Highlights · Net sales increased by $8.7 million, or 16.5%, year over year, from $52.7 million in 2013 to $61.4 million in 2014. · Gross profit grew by approximately 17.9% from $25.7 million in 2013 to $30.3 million in 2014. · Cash and] [FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): April 15, 2015 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue, Xianyang City, Shaanxi Province, People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ¨ ¨ ¨]
BSPM [Biostar Pharmaceuticals] 10-K: (Original Filing)
[FORM 10-K (Mark One) x December 31, 2014 For the fiscal year ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 86-29-33686638 (Former name, former] [Biostar Pharmaceuticals, Inc. List of subsidiaries As of December 31, 2014 Name Place of incorporation Shaanxi Biostar Biotech Ltd People’s Republic of China Shaanxi Aoxing Pharmaceutical Co. Ltd. People’s Republic of China Shaanxi Weinan Haren Pharmaceuticals, Ltd. People’s Republic of China EX-21 2 ex21.htm EX-21] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors of Biostar Pharmaceuticals, Inc. Clement C. W. Chan & Co. Certified Public Accountants Hong Kong April 15, 2015 EX-23.1 3 ex23-1.htm EX-23.1] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. Clement C. W. Chan & Co. Certified Public Accountants Hong Kong April 15, 2015 EX-23.2 4 ex23-2.htm EX-23.2] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. Mazars CPA Limited Certified Public Accountants Hong Kong April 15, 2015 EX-23.3 5 ex23-3.htm EX-23.3] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. Mazars CPA Limited Certified Public Accountants Hong Kong April 15, 2015 EX-23.4 6 ex23-4.htm EX-23.4] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this Annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this Annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Dated: April 15, 2015 Ronghua Wang Chief Executive Officer EX-32.1 9 ex32-1.htm EX-32.1] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Dated: April 15, 2015 Qinghua Liu Interim Chief Financial Officer EX-32.2 10 ex32-2.htm EX-32.2]
WX [WuXi PharmaTech (Cayman)] 20-F: (Original Filing)
[WuXi PharmaTech (Cayman) Inc. Page INTRODUCTION 1 2 PART I. ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS 3 ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE 3 ITEM 3. KEY INFORMATION 3 ITEM 4. INFORMATION ON THE COMPANY 27 ITEM 4A. UNRESOLVED STAFF COMMENTS 49 ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS 49 ITEM 6. DIRECTORS, SENIOR MANAGEMENT] [Execution Version Dated 16 February 2015 WUXI PHARMATECH (CAYMAN) INC. AS BORROWER WUXI APPTEC HOLDING COMPANY, INC. WUXI APPTEC, INC. WUXI APPTEC (BVI) INC. WUXI APPTEC (HONG KONG) LIMITED AS ORIGINAL GUARANTORS CITIGROUP GLOBAL MARKETS ASIA LIMITED AS COORDINATING ARRANGER AND CITICORP INTERNATIONAL LIMITED AS AGENT FACILITY AGREEMENT FOR US$165,000,000 SENIOR TERM AND REVOLVING LOAN FACILITY CONTENTS Clause Page 1.] [LIST OF SUBSIDIARIES Name Abbreviation Place of Incorporation WuXi AppTec (BVI) Inc. WXAT BVI British Virgin Islands WuXi AppTec Co., Ltd. WXAT PRC WuXi AppTec (Shanghai) Co., Ltd. WASH PRC Shanghai SynTheAll Pharmaceutical Co., Ltd. STA PRC WuXi AppTec (Suzhou) Co., Ltd. WASZ PRC WuXi AppTec (Tianjin) Co., Ltd. WATJ PRC WuXi AppTec Holding Company, Inc. AppTec Holding WuXi AppTec,] [Certification by the Chief Executive Officer I, Ge Li, certify that: 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered] [Certification by the Chief Financial Officer I, Edward Hu, certify that: 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered] [Section 906 of the Sarbanes-Oxley Act of 2002 Ge Li Chief Executive Officer EX-13.1 6 d796029dex131.htm EX-13.1] [Certification by the Chief Financial Officer Edward Hu Chief Financial Officer EX-13.2 7 d796029dex132.htm EX-13.2] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Registration Statement No. 333-182917 on Form S-8 of our reports dated April 15, 2015, relating to the consolidated financial statements and financial statement schedule of Wuxi PharmaTech (Cayman) Inc. and its subsidiaries, and the effectiveness of Wuxi PharmaTech (Cayman) Inc. and its subsidiaries internal]
BSPM [Biostar Pharmaceuticals] 10-K: FORM 10-K (Mark One) x December 31, 2014
[FORM 10-K (Mark One) x December 31, 2014 For the fiscal year ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 86-29-33686638 (Former name, former] [Biostar Pharmaceuticals, Inc. List of subsidiaries As of December 31, 2014 Name Place of incorporation Shaanxi Biostar Biotech Ltd People’s Republic of China Shaanxi Aoxing Pharmaceutical Co. Ltd. People’s Republic of China Shaanxi Weinan Haren Pharmaceuticals, Ltd. People’s Republic of China EX-21 2 ex21.htm EX-21] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors of Biostar Pharmaceuticals, Inc. Clement C. W. Chan & Co. Certified Public Accountants Hong Kong April 15, 2015 EX-23.1 3 ex23-1.htm EX-23.1] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. Clement C. W. Chan & Co. Certified Public Accountants Hong Kong April 15, 2015 EX-23.2 4 ex23-2.htm EX-23.2] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. Mazars CPA Limited Certified Public Accountants Hong Kong April 15, 2015 EX-23.3 5 ex23-3.htm EX-23.3] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. Mazars CPA Limited Certified Public Accountants Hong Kong April 15, 2015 EX-23.4 6 ex23-4.htm EX-23.4] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this Annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this Annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Dated: April 15, 2015 Ronghua Wang Chief Executive Officer EX-32.1 9 ex32-1.htm EX-32.1] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Dated: April 15, 2015 Qinghua Liu Interim Chief Financial Officer EX-32.2 10 ex32-2.htm EX-32.2]
WX [WuXi PharmaTech (Cayman)] 20-F: WuXi PharmaTech (Cayman) Inc. Page INTRODUCTION 1 2
[WuXi PharmaTech (Cayman) Inc. Page INTRODUCTION 1 2 PART I. ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS 3 ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE 3 ITEM 3. KEY INFORMATION 3 ITEM 4. INFORMATION ON THE COMPANY 27 ITEM 4A. UNRESOLVED STAFF COMMENTS 49 ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS 49 ITEM 6. DIRECTORS, SENIOR MANAGEMENT] [Execution Version Dated 16 February 2015 WUXI PHARMATECH (CAYMAN) INC. AS BORROWER WUXI APPTEC HOLDING COMPANY, INC. WUXI APPTEC, INC. WUXI APPTEC (BVI) INC. WUXI APPTEC (HONG KONG) LIMITED AS ORIGINAL GUARANTORS CITIGROUP GLOBAL MARKETS ASIA LIMITED AS COORDINATING ARRANGER AND CITICORP INTERNATIONAL LIMITED AS AGENT FACILITY AGREEMENT FOR US$165,000,000 SENIOR TERM AND REVOLVING LOAN FACILITY CONTENTS Clause Page 1.] [LIST OF SUBSIDIARIES Name Abbreviation Place of Incorporation WuXi AppTec (BVI) Inc. WXAT BVI British Virgin Islands WuXi AppTec Co., Ltd. WXAT PRC WuXi AppTec (Shanghai) Co., Ltd. WASH PRC Shanghai SynTheAll Pharmaceutical Co., Ltd. STA PRC WuXi AppTec (Suzhou) Co., Ltd. WASZ PRC WuXi AppTec (Tianjin) Co., Ltd. WATJ PRC WuXi AppTec Holding Company, Inc. AppTec Holding WuXi AppTec,] [Certification by the Chief Executive Officer I, Ge Li, certify that: 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered] [Certification by the Chief Financial Officer I, Edward Hu, certify that: 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered] [Section 906 of the Sarbanes-Oxley Act of 2002 Ge Li Chief Executive Officer EX-13.1 6 d796029dex131.htm EX-13.1] [Certification by the Chief Financial Officer Edward Hu Chief Financial Officer EX-13.2 7 d796029dex132.htm EX-13.2] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Registration Statement No. 333-182917 on Form S-8 of our reports dated April 15, 2015, relating to the consolidated financial statements and financial statement schedule of Wuxi PharmaTech (Cayman) Inc. and its subsidiaries, and the effectiveness of Wuxi PharmaTech (Cayman) Inc. and its subsidiaries internal]
